DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05419726

Recruiting

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

20

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Supraclavicular temperature with cold exposure•Caloric intake•Basal metabolic rate

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05419726
Org study ID22-000718

Timeline

Milestones

Study first posted2022-06-15actual
Study start2023-02-01actual
Last update posted2025-05-11actual
Primary completion2026-01-01estimated
Study completion2026-02-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted
Sampling methodNon probability sample

Study population text

Adult \>18 years of age, non-diabetic but obese The study is a non-randomized single center study. Subjects who are to be started by their physician or endocrinologist on semaglutide for weight loss, and are willing to participate.

Inclusion criteria

•Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
•>18 years of age and willing to participate
•Male or post-menopausal females

Exclusion criteria

•History of prior neck surgery and /or neck irradiation
–Use of beta blocker agents
–Use of any other glucose lowering medication
–History of neuropathic disorders (e.g. diabetic neuropathy)
–Diabetic patients
–Individuals without normal thyroid function
–Individuals with cancer
–Any significant chronic disease or renal, hepatic or endocrine disease
–Current smokers
–Inability of patient to provide consent either for medical reasons or psychiatric reasons

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Weight & body composition
1

Weight & body composition

1 endpoint
Primary/protocol endpoint/low confidence

basal metabolic rate

Time frame:20 weeks

change from baseline, descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

change in supraclavicular temperature with cold exposure

Time frame:20weeks

change from baseline, descriptive

Primary/protocol endpoint/low confidence

change in caloric intake

Time frame:20weeks

change from baseline, improvement

Publications (20)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.